Migraine Briefs

IV eptinezumab holds promise for preventive treatment of episodic migraine


 

Key clinical point : Intravenous (IV) eptinezumab could be a safe and effective preventive therapy for adult patients with episodic migraine.

Main finding : Eptinezumab 100 and 300 mg significantly reduced monthly migraine days across weeks 1-12 compared with the placebo (difference from placebo for 100 and 300 mg: –0.69; P = .0182 and –1.11; P = .0001, respectively). Safety and tolerability of eptinezumab across doses were acceptable compared with placebo, with no dose-related trend in the nature, frequency, or severity of treatment-related adverse events.

Study details : In phase 3, multicenter, double-blind, parallel-group study, 888 patients were randomly assigned to IV eptinezumab (30, 100, and 300 mg) or placebo administered every 12 weeks.

Disclosures: The study was funded by H. Lundbeck A/S, Copenhagen, Denmark. Some of the authors were full-time employees of or contracted to Lundbeck Seattle BioPharmaceuticals, Inc. (previously known as Alder BioPharmaceuticals, Inc.), a subsidiary H. Lundbeck A/S. Some also were stockholders of Lundbeck Seattle BioPharmaceuticals, Inc.

Citation: Ashina M et al. Cephalalgia. 2020 Feb 19. doi: 10.1177/0333102420905132 .

Next Article: